Carl Dambkowski Sells 2,725 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 2,725 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $36.96, for a total value of $100,716.00. Following the completion of the sale, the insider now owns 241,723 shares of the company's stock, valued at $8,934,082.08. The trade was a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, May 7th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The shares were sold at an average price of $35.75, for a total value of $97,418.75.
• On Wednesday, April 2nd, Carl Dambkowski sold 3,860 shares of Apogee Therapeutics stock. The shares were sold at an average price of $36.22, for a total value of $139,809.20.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock traded down $0.85 during trading on Monday, reaching $40.13. 921,636 shares of the company traded hands, compared to its average volume of 541,384. The firm has a market capitalization of $1.85 billion, a PE ratio of -16.58 and a beta of 1.38. Apogee Therapeutics, Inc. has a 1-year low of $26.20 and a 1-year high of $63.50. The company has a 50 day moving average price of $36.39 and a 200-day moving average price of $39.48.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.19) by $0.24. Equities research analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

APGE has been the topic of a number of analyst reports. Citigroup assumed coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $94.60.

Institutional Trading of Apogee Therapeutics

Several hedge funds have recently bought and sold shares of APGE. Brooklyn Investment Group acquired a new position in Apogee Therapeutics during the first quarter worth $42,000. GF Fund Management CO. LTD. acquired a new stake in shares of Apogee Therapeutics in the 4th quarter worth about $43,000. AlphaQuest LLC acquired a new stake in shares of Apogee Therapeutics in the 1st quarter worth about $43,000. GAMMA Investing LLC lifted its position in Apogee Therapeutics by 3,560.1% in the 1st quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock valued at $202,000 after acquiring an additional 5,269 shares in the last quarter. Finally, Optimize Financial Inc acquired a new position in Apogee Therapeutics during the 4th quarter valued at about $203,000. Institutional investors and hedge funds own 79.04% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.